The Company has been at the forefront in understanding molecular, immunologic, microbial and metabolic drivers of oral-gut inflammatory diseases in humans and animals since 2017. It has amassed a pipeline of novel combinations of functional ingredients, or single small molecule drugs that have applications in periodontitis, gingivitis, stomatitis, and cavities and gut health.